TCMCB07 for Cachexia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Quotient Sciences -- Miami, Inc., Miami, FL
Cachexia
TCMCB07 - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether the experimental drug TCMCB07 can help treat cancer cachexia, a syndrome that causes weight loss, anorexia, weakness, and anemia. TCMCB07 is a medication that is used to treat cachexia, and it is available for free. This medication was previously approved by the FDA for a different condition.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Cachexia

Study Objectives

5 Primary · 2 Secondary · Reporting Duration: 6 months

6 Months
Number of participants with abnormal vital signs
Number of people with abnormal Electrocardiograms
Number of people with abnormal laboratory test results
Number of people with abnormal physical examinations
Number of people with an Adverse Event Assessment
Peak Plasma Concentration (Cmax)
6 months
Area under the plasma concentration versus time curve (AUC)

Trial Safety

Safety Progress

1 of 3

Other trials for Cachexia

Trial Design

2 Treatment Groups

TCMCB07
1 of 2
TCMCB07 Matching Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

97 Total Participants · 2 Treatment Groups

Primary Treatment: TCMCB07 · Has Placebo Group · Phase 1

TCMCB07
Drug
Experimental Group · 1 Intervention: TCMCB07 · Intervention Types: Drug
TCMCB07 Matching Placebo
Drug
PlaceboComparator Group · 1 Intervention: TCMCB07 Matching Placebo · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: Quotient Sciences -- Miami, Inc. · Miami, FL
Photo of Miami 1Photo of Miami 2Photo of Miami 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Cachexia
0 CompletedClinical Trials

Who is running the clinical trial?

Endevica BioLead Sponsor
Maria Bermudez, MD, CPIPrincipal InvestigatorQuotient Sciences

Eligibility Criteria

Age 18 - 65 · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are aged 18 to 55 years inclusive.
BMI > 30.0 kg/m2 is considered clinically significant.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.